Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation

References

• Lekakis LJ, Moskowitz CH. The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma in the era of CAR-T cell therapy. Hemasphere. 2019;3(6):e295.
   PubMed Web of Science ®Google Scholar
• Zoellner AK, Unterhalt M, Stilgenbauer S, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8(9):e648–e57.
   PubMed Web of Science ®Google Scholar
• Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295–1312.
   PubMed Web of Science ®Google Scholar
• Damaj G, Cornillon J, Bouabdallah K, et al. Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Bone Marrow Transplant. 2017;52(7):941–949.
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood. 1993;81(5):1137–1145.
   PubMed Web of Science ®Google Scholar
• Frankiewicz A, Saduś-Wojciechowska M, Najda J, et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemp Oncol (Pozn). 2018;22(2):113–117.
   PubMed Web of Science ®Google Scholar
• Puig N, de la Rubia J, Remigia MJ, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma. 2006;47(8):1488–1494.
   PubMed Web of Science ®Google Scholar
• Visani G, Stefani PM, Capria S, et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood. 2014;124(19):3029–3031.
   PubMed Web of Science ®Google Scholar
• Chantepie SP, Garciaz S, Tchernonog E, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from lymphoma study association (LYSA) centers. Am J Hematol. 2018;93(6):729–735.
   PubMed Web of Science ®Google Scholar
• Saleh K, Danu A, Koscielny S, et al. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. Leuk Lymphoma. 2018;59(11):2580–2587.
   PubMed Web of Science ®Google Scholar
• AlJohani NI, Nasani M, Ahmed HE, et al. Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: a retrospective single-center study. Hematol Oncol Stem Cell Ther. 2021;14(4):327–335.
   PubMedGoogle Scholar
• Lachance S, Bourguignon A, Boisjoly JA, et al. Impact of implementing a Bendamustine-Based conditioning regimen on outcomes of autologous stem cell transplantation in lymphoma while novel cellular therapies emerge. Transplant Cell Ther. 2023;29(1):34. e1- e7.
   Google Scholar
• Garciaz S, Coso D, Schiano de Collela JM, et al. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transplant. 2016;51(2):319–321.
   PubMed Web of Science ®Google Scholar
• Hueso T, Gastinne T, Garciaz S, et al. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from lymphoma study association (LYSA) centers. Bone Marrow Transplant. 2020;55(6):1076–1084.
   PubMed Web of Science ®Google Scholar
• Isidori A, Christofides A, Visani G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma. 2016;57(11):2499–2509.
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Prka Z, Jaksic O, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality. Am J Hematol. 2019;94(2):E42–E43. E3.
   PubMed Web of Science ®Google Scholar
• Mohty M, Belhocine R, Aoudjhane M, et al. TEAM conditioning (thiotepa, etoposide, cytarabine, melphalan) prior to autologous hematopoietic stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: final results from a prospective multicenter study. Blood. 2019;134(Supplement_1):786–786.
   Google Scholar
• Frietsch JJ, Miethke J, Linke P, et al. Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma. Bone Marrow Transplant. 2022;57(7):1164–1170.
   PubMed Web of Science ®Google Scholar
• Olivieri J, Mosna F, Pelosini M, et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from fondazione italiana linfomi. Biol Blood Marrow Transplant. 2018;24(9):1814–1822.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous Stem-Cell transplantation in Mantle-Cell lymphoma. N Engl J Med. 2017;377(13):1250–1260.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-Cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119–3128.
   PubMed Web of Science ®Google Scholar
• Riedell PA, Hwang WT, Nastoupil LJ, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2022;28(10):669–676.
   Google Scholar
• Bishop MR, Dickinson M, Purtill D, et al. Second-Line tisagenlecleucel or standard care in aggressive B-Cell lymphoma. N Engl J Med. 2022;386(7):629–639.
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as Second-Line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386(7):640–654.
   PubMed Web of Science ®Google Scholar
• Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–2308.
   PubMed Web of Science ®Google Scholar